Sanofi sues Eli Lilly for patent infringement

French pharmaceutical giant Sanofi has said it is suing US rival Eli Lilly in an American court for infringing four patents relating to its diabetes treatments.

The lawsuit, lodged in the state of Delaware, was triggered by Eli Lilly's notification last month that it plans to ask the US Food and Drug Administration (FDA) for permission to put a new diabetes treatment on the market.

"Sanofi announced today (Thursday) that it filed a patent infringement suit against Eli Lilly and Company," the French company said in a statement.

Sanofi is seeking to protect its insulin Lantus and insulin pen Lantus SoloStar, which generate a sixth of the company's sales.

Eli Lilly is challenging Sanofi patents listed for Lantus and has stated that it will not launch its own product before the expiry of Sanofi's patent on the drug's active ingredient, which is in force until mid-February 2015, Sanofi said in its statement.

Mark Clark, analyst at Deutsche Bank, said the lengthy legal process begun by Sanofi would probably delay Eli Lilly's launch of the drug to market until at least 2016.

An Eli Lilly spokesman told AFP it was studying the complaint and had no immediate comment.

add to favorites email to friend print save as pdf

Related Stories

China targets Germany's Bayer in drug price probe

Sep 13, 2013

Chinese authorities have visited an office of German pharmaceutical giant Bayer, the company said Friday, making it the latest target in a probe of foreign drug firms over high prices.

US health watchdog rejects Sanofi's MS drug

Dec 30, 2013

French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments